Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.
about
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studiesTreatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitorsFour-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC StudyDipeptidyl Peptidase-4 Inhibitor Alarms: Is Heart Failure Caused by a Class Effect?Prescribing differences in family practice for diabetic patients in Germany according to statutory or private health insurance: the case of DPP-4-inhibitors and GLP-1-agonists.Cardiac implications of hypoglycaemia in patients with diabetes - a systematic reviewA systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs.Antiatherothrombotic effects of dipeptidyl peptidase inhibitors.A review of gliptins for 2014.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
P2860
Q26765047-6678AB82-C6C1-4F0B-9864-3FC8FE5E3EE2Q27021870-EDA995B3-D454-4CB5-BDC3-0E92EED05099Q35661969-B96A957A-0944-4BDB-A140-97DAF4F356D6Q35790625-325EDE24-A65F-491A-AED4-8E3EBE587278Q36168227-728319DA-F784-4723-9880-650AC8FEEA2FQ37361386-9D9302A1-15A7-4FAB-B001-837052BBE2DFQ37610459-3D0A18E0-4A06-4DAF-9166-16D07AC8A2DBQ38195527-6F970DF9-2A55-4C55-94DF-943C8954536BQ38266290-A61E18F4-D053-47A5-9CBA-A4D603654F16Q38335751-6F6CE78A-E12F-4D50-BFA5-08E0A89F1A5AQ38644587-B86E3EBA-E11F-46B0-91C8-2B1BB2900F20Q38922177-74A93596-B08B-43B2-8B4D-478460B13DEDQ44061187-24827E5C-9EED-4956-8B95-3881A0BEF8C6Q49283683-1DAEBF0E-2051-4370-AEF2-7BB84F5AA389
P2860
Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Prognostic implications of DPP ...... prospective DiaRegis registry.
@en
Prognostic implications of DPP ...... prospective DiaRegis registry.
@nl
type
label
Prognostic implications of DPP ...... prospective DiaRegis registry.
@en
Prognostic implications of DPP ...... prospective DiaRegis registry.
@nl
prefLabel
Prognostic implications of DPP ...... prospective DiaRegis registry.
@en
Prognostic implications of DPP ...... prospective DiaRegis registry.
@nl
P2093
P2860
P356
P1476
Prognostic implications of DPP ...... prospective DiaRegis registry.
@en
P2093
P2860
P304
P356
10.1111/IJCP.12179
P577
2013-08-28T00:00:00Z